UNSPSC 51172130: Fenpipramide or fenpipramide hydrochloride

This classification denotes an antispasmotic agent with the molecular formulas C21H26N2O and C21H26N2O.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 88445508X3 and KJ2V75P034, chemically known as 1-piperidinebutyramide, alpha,alpha-diphenyl- but generally known as fenpipramide, which bears US NIH Compound Identifier 65573. European Medicines Agency schedules Fenpipramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB07588MIG and SUB02123MIG.

UNSPSC 51172130 Fenpipramide or fenpipramide hydrochloride is a Commodity code that shows minimal alignment with recent state and local procurement activity. The three most recent opportunities tagged to this code involve offender drug testing services (specimen collection and immunoassay screening), a market-research RFI on direct-to-manufacturer pharmacy programs, and a multistate cooperative purchasing contract for generic pharmaceuticals and OTC products. None of these solicitations name fenpipramide specifically or indicate that this particular pharmaceutical is being procured. The code's nominal scope — a specific pharmaceutical active ingredient — does not match the work actually being solicited, which centers on testing services delivery, pharmacy benefit program design, and broad-based generic drug supply agreements rather than procurement of fenpipramide itself.

Activity under this code appears sparse and misdirected. The Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services, with proposals due July 23, 2026 and an estimated contract value of $600,000 over two years; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration issued an RFP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026; and the Texas Health and Human Services Commission issued a market-research RFI on direct-to-manufacturer prescription programs posted April 3, 2026. Fenpipramide does not appear as a line item in any of these opportunities. Business development professionals should verify whether this code genuinely reflects state or local demand for this specific pharmaceutical or whether the tagging reflects a procurement system miscategorization.